NCT00699504

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 67 (actual)
• Sponsor: The Medicines Company · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	cangrelor	IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
DRUG	cangrelor	30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
DRUG	cangrelor	60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
DRUG	moxifloxacin	400 mg orally. Placebo IV bolus and infusion.
DRUG	placebo	placebo IV and oral

Timeline

• Start date: 2008-06-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2008-06-18
• Last updated: 2012-01-18

Locations

1 site across 1 country: United States